156 related articles for article (PubMed ID: 22911936)
1. On the interchangeability of biologic drug products.
Endrenyi L; Chang C; Chow SC; Tothfalusi L
Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
[TBL] [Abstract][Full Text] [Related]
2. Statistical methods for assessing interchangeability of biosimilars.
Chow SC; Yang LY; Starr A; Chiu ST
Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
[TBL] [Abstract][Full Text] [Related]
3. Scientific considerations for assessing biosimilar products.
Chow SC; Wang J; Endrenyi L; Lachenbruch PA
Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
[TBL] [Abstract][Full Text] [Related]
4. Statistical and regulatory considerations in assessments of interchangeability of biological drug products.
Tóthfalusi L; Endrényi L; Chow SC
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S5-11. PubMed ID: 24832831
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.
Hsieh TC; Chow SC; Yang LY; Chi E
Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403
[TBL] [Abstract][Full Text] [Related]
6. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
Szeto KJ; Wolanski M
Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
[TBL] [Abstract][Full Text] [Related]
7. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
[TBL] [Abstract][Full Text] [Related]
8. Similar names for similar biologics.
Casadevall N; Felix T; Strober BE; Warnock DG
BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
[TBL] [Abstract][Full Text] [Related]
9. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
10. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Endrenyi L; Markus R
J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
[TBL] [Abstract][Full Text] [Related]
11. Sowing confusion in the field: the interchangeable use of biosimilar terminology.
McKinley L; Kelton JM; Popovian R
Curr Med Res Opin; 2019 Apr; 35(4):619-621. PubMed ID: 30556742
[TBL] [Abstract][Full Text] [Related]
12. [Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].
Ferreira Neto PTP; Nunes PHC; Vargas MA
Cad Saude Publica; 2019; 35(10):e00053519. PubMed ID: 31618379
[TBL] [Abstract][Full Text] [Related]
13. From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework.
Karalis VD
Drug Res (Stuttg); 2016 Jan; 66(1):1-6. PubMed ID: 25894088
[TBL] [Abstract][Full Text] [Related]
14. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.
Zhang N; Yang J; Chow SC; Endrenyi L; Chi E
Stat Med; 2013 Feb; 32(3):424-33. PubMed ID: 22933127
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
[TBL] [Abstract][Full Text] [Related]
16. Assessing biosimilarity and interchangeability of biosimilar products.
Chow SC
Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
[No Abstract] [Full Text] [Related]
17. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
[TBL] [Abstract][Full Text] [Related]
18. An adapted F-test for homogeneity of variability in follow-on biological products.
Yang J; Zhang N; Chow SC; Chi E
Stat Med; 2013 Feb; 32(3):415-23. PubMed ID: 22933180
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
20. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A; Furtner D; Melsheimer R; Molloy PJ
Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
